Amneal Pharmaceuticals vs BioMarin Pharmaceutical
AMRX and BMRN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMRX and BMRN compare
BioMarin Pharmaceutical is the larger company, worth 1.6 times as much as Amneal Pharmaceuticals ($11.1B against $6.8B).
On earnings, Amneal Pharmaceuticals is cheaper: it trades at 50.9× trailing earnings, against 151× for BioMarin Pharmaceutical.
BioMarin Pharmaceutical grew revenue faster over the last twelve months (11.2% versus 8.9% for Amneal Pharmaceuticals).
Amneal Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 4.2% compared with 2.1% at BioMarin Pharmaceutical.
Amneal Pharmaceuticals scores higher on the StockData Score (12 against 8 for BioMarin Pharmaceutical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMRX | BMRN |
|---|---|---|
| Size and price | ||
| Market cap | $6.8B | $11.1B |
| Share price | $21.38 | $57.23 |
| Change, 1 year | 79.7% | 3.5% |
| Change, 5 years | 363% | −37.4% |
| Beta (5Y) | 1.07 | 0.59 |
| Employees | 8,500 | 3,221 |
| StockData Score | ||
| Total score | 12 (better) | 8 |
| Valuation score | 0 | 1 (better) |
| Growth score | 5 (better) | 3 |
| Performance score | 5 (better) | 2 |
| Health score | 2 | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 50.9× (better) | 151× |
| P/S | 2.1× (better) | 3.3× |
| P/B | 12.9× | 1.8× (better) |
| EV/EBITDA | 20.1× (better) | 47.6× |
| P/FCF | 77.4× | 15.0× (better) |
| PEG | – | 4.44 |
| FCF yield | 1.3% | 6.7% (better) |
| Fair value | $13.10 | $30.00 |
| Margin of safety | −63.2% (better) | −90.8% |
| Growth | ||
| Revenue growth (TTM) | 8.9% | 11.2% (better) |
| Revenue growth, 5Y average | 8.7% | 11.6% (better) |
| Net income growth (TTM) | 2159% (better) | −88.9% |
| EPS growth (TTM) | 2000% (better) | −88.7% |
| EPS growth, 5Y average | −18.5% | −16.7% (better) |
| Profitability | ||
| Gross margin | 40.2% | 76.1% (better) |
| Operating margin | 15.0% (better) | 4.4% |
| Net margin | 4.2% (better) | 2.1% |
| FCF margin | 2.8% | 21.7% (better) |
| Return on equity | 63.2% (better) | 1.2% |
| Return on invested capital | 16.3% (better) | 1.0% |
| Financial health | ||
| Debt / equity | 5.53 | 0.66 (better) |
| Net debt / EBITDA | 5.81 (better) | 10.96 |
| Interest coverage | – | 2.0× |
| Current ratio | 1.87 | 2.39 (better) |
| Altman Z-score | 1.88 (better) | 1.84 |
| Piotroski F-score | 7 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 52.7% | 101% |
| Held by insiders | 60.7% | 0.52% |
| Insider net buying, 12 months | −$7.7M | −$4.3M (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 9.1% | 7.3% |
Go deeper
- AMRX stock overview
- AMRX income statement
- AMRX valuation and score
- BMRN stock overview
- BMRN income statement
- BMRN valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.